“The cell identification technology, which had required our best efforts back then, fell short of the advanced technology level of today.”

Still, the drug as an end-product has been tested and proved of its safety and efficacy on patients, Lee stressed.

“This does not mean that our past shortcomings should be forgiven,” he said.

“But we continue to remain confident over the safety and effectiveness of Invossa.”

The company will continue to develop novel drugs and gene therapy pipelines, seeking to recover trust from investors, he added.

The Ministry of Food and Drug Safety on Wednesday finalized its decision to revoke the permit for Invossa. Meanwhile, prosecutors are currently conducting a probe to check the approval procedure of the drug.

As for the patients who have taken Invossa shots, the company will provide a 15-year follow-up medical checkup for all registered patients, in collaboration with 20 hospitals nationwide, according to Yoo Soo-Hyun, the managing director at KLS. Some 80 billion won ($68 million) has been allocated in the company’s business report for the purpose.
 

Having started to collect patient registration data in mid-April, the company has so far collected information from 1,725 patients and is expecting to gather 3,700 by October.

When asked whether the 15-year follow-up plan is a plot to use the test results to develop a new alternative drug, CEO Lee left the room without taking the question, citing ongoing legal procedures.

Following the press conference, OhKims Law & Co. which represents over 760 patients that have taken Invossa, expressed discomfort over the company’s investor-focused stance.

“All of Kolon’s narrative so far focuses on investors. CEO Lee’s claim of clearing uncertainty is about the company value and not patient anxiety,” the law firm said in a press release, “We urge KLS to resume accountability as a pharmaceutical firm whose foremost value is in treating patients.”

By Lim Jeong-yeo (kaylalim@heraldcorp.com)